U.S. Markets close in 5 hrs 8 mins
  • S&P 500

    4,130.38
    +2.39 (+0.06%)
     
  • Dow 30

    33,592.33
    -153.07 (-0.45%)
     
  • Nasdaq

    13,946.92
    +96.92 (+0.70%)
     
  • Russell 2000

    2,226.56
    -7.23 (-0.32%)
     
  • Crude Oil

    60.22
    +0.52 (+0.87%)
     
  • Gold

    1,741.70
    +9.00 (+0.52%)
     
  • Silver

    25.36
    +0.49 (+1.98%)
     
  • EUR/USD

    1.1933
    +0.0016 (+0.1313%)
     
  • 10-Yr Bond

    1.6640
    -0.0110 (-0.66%)
     
  • Vix

    16.92
    +0.01 (+0.06%)
     
  • GBP/USD

    1.3734
    -0.0008 (-0.0563%)
     
  • USD/JPY

    109.2060
    -0.1700 (-0.1554%)
     
  • BTC-USD

    63,000.04
    +2,448.21 (+4.04%)
     
  • CMC Crypto 200

    1,345.09
    +51.10 (+3.95%)
     
  • FTSE 100

    6,891.14
    +2.02 (+0.03%)
     
  • Nikkei 225

    29,751.61
    +212.88 (+0.72%)
     

How Much Of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Do Institutions Own?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

If you want to know who really controls Milestone Pharmaceuticals Inc. (NASDAQ:MIST), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. We also tend to see lower insider ownership in companies that were previously publicly owned.

Milestone Pharmaceuticals is a smaller company with a market capitalization of US$220m, so it may still be flying under the radar of many institutional investors. In the chart below, we can see that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about Milestone Pharmaceuticals.

View our latest analysis for Milestone Pharmaceuticals

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Milestone Pharmaceuticals?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Milestone Pharmaceuticals already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Milestone Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

It looks like hedge funds own 20% of Milestone Pharmaceuticals shares. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Our data shows that RTW Investments, LP is the largest shareholder with 14% of shares outstanding. RA Capital Management, L.P. is the second largest shareholder owning 8.1% of common stock, and BDC Capital Inc. holds about 8.0% of the company stock. Furthermore, CEO Joseph Oliveto is the owner of 0.9% of the company's shares.

On further inspection, we found that more than half the company's shares are owned by the top 6 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Milestone Pharmaceuticals

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own some shares in Milestone Pharmaceuticals Inc.. In their own names, insiders own US$3.1m worth of stock in the US$220m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.

General Public Ownership

The general public, with a 19% stake in the company, will not easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With a stake of 37%, private equity firms could influence the Milestone Pharmaceuticals board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 2 warning signs for Milestone Pharmaceuticals that you should be aware of.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.